Justin M Oldham1, Disha Kumar2, Cathryn Lee3, Shruti B Patel4, Stephenie Takahashi-Manns5, Carley Demchuk6, Mary E Strek6, Imre Noth6. 1. Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL. Electronic address: justin.oldham@uchospitals.edu. 2. Section of Endocrinology, Diabetes, and Metabolism, University of Chicago, Chicago, IL. 3. Department of Medicine, University of Chicago, Chicago, IL. 4. Division of Pulmonary and Critical Care Medicine, Loyola University Medical Center, Chicago, IL. 5. Department of Critical Care Medicine, The Intensivist Group of Pennsylvania, Philadelphia, PA. 6. Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL.
Abstract
BACKGROUND: A significant minority of patients with idiopathic pulmonary fibrosis (IPF) display features of autoimmunity without meeting the criteria for overt connective tissue disease. A link between IPF and other immune-mediated processes, such as hypothyroidism (HT), has not been reported. In this investigation, we aimed to determine whether HT is associated with IPF and if outcomes differ between patients with IPF with and without HT. METHODS: A retrospective case-control analysis was conducted. Of 311 patients referred to the University of Chicago Interstitial Lung Disease Center with an initial diagnosis of IPF, 196 met the inclusion criteria and were included in the final analysis. Each case was matched 1:1 by age, sex, and race to a control subject with COPD. RESULTS: HT was identified in 16.8% of cases and 7.1% of control subjects (OR, 2.7; 95% CI, 1.31-5.54; P = .01). Among patients with IPF, HT was associated with reduced survival time (P < .001) and was found to be an independent predictor of mortality in multivariable Cox regression analysis (hazard ratio, 2.12; 95% CI, 1.31-3.43; P = .002). A secondary analysis of two IPF clinical trial datasets supports these findings. CONCLUSIONS: HT is common among patients with IPF, with a higher prevalence than in those with COPD and the general population. The presence of HT also predicts mortality in IPF, a finding that may improve future prognostication models. More research is needed to determine the biologic link between IPF and HT and how the presence of thyroid disease may influence disease progression.
BACKGROUND: A significant minority of patients with idiopathic pulmonary fibrosis (IPF) display features of autoimmunity without meeting the criteria for overt connective tissue disease. A link between IPF and other immune-mediated processes, such as hypothyroidism (HT), has not been reported. In this investigation, we aimed to determine whether HT is associated with IPF and if outcomes differ between patients with IPF with and without HT. METHODS: A retrospective case-control analysis was conducted. Of 311 patients referred to the University of Chicago Interstitial Lung Disease Center with an initial diagnosis of IPF, 196 met the inclusion criteria and were included in the final analysis. Each case was matched 1:1 by age, sex, and race to a control subject with COPD. RESULTS:HT was identified in 16.8% of cases and 7.1% of control subjects (OR, 2.7; 95% CI, 1.31-5.54; P = .01). Among patients with IPF, HT was associated with reduced survival time (P < .001) and was found to be an independent predictor of mortality in multivariable Cox regression analysis (hazard ratio, 2.12; 95% CI, 1.31-3.43; P = .002). A secondary analysis of two IPF clinical trial datasets supports these findings. CONCLUSIONS:HT is common among patients with IPF, with a higher prevalence than in those with COPD and the general population. The presence of HT also predicts mortality in IPF, a finding that may improve future prognostication models. More research is needed to determine the biologic link between IPF and HT and how the presence of thyroid disease may influence disease progression.
Authors: Ratnasingam Nithiyananthan; Joanne M Heward; Amit Allahabadia; Jayne A Franklyn; Stephen C L Gough Journal: Thyroid Date: 2002-01 Impact factor: 6.568
Authors: T E King; M I Schwarz; K Brown; J A Tooze; T V Colby; J A Waldron; A Flint; W Thurlbeck; R M Cherniack Journal: Am J Respir Crit Care Med Date: 2001-09-15 Impact factor: 21.405
Authors: M P Vanderpump; W M Tunbridge; J M French; D Appleton; D Bates; F Clark; J Grimley Evans; D M Hasan; H Rodgers; F Tunbridge Journal: Clin Endocrinol (Oxf) Date: 1995-07 Impact factor: 3.478
Authors: Justin M Oldham; Ayodeji Adegunsoye; Eleanor Valenzi; Cathryn Lee; Leah Witt; Lena Chen; Aliya N Husain; Steven Montner; Jonathan H Chung; Vincent Cottin; Aryeh Fischer; Imre Noth; Rekha Vij; Mary E Strek Journal: Eur Respir J Date: 2016-04-21 Impact factor: 16.671
Authors: Edward P Manning; Ashley Losier; Nkiruka Emeagwali; Changwan Ryu; Shyoko Honiden Journal: Am J Respir Crit Care Med Date: 2019-06-15 Impact factor: 21.405
Authors: Mason T Breitzig; Matthew D Alleyn; Richard F Lockey; Narasaiah Kolliputi Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-09-27 Impact factor: 5.464
Authors: David N O'Dwyer; Bonnie R Wang; Vivek Nagaraja; Kevin R Flaherty; Dinesh Khanna; Susan Murray; Pier Valerio Mari; Eric S White Journal: Ann Am Thorac Soc Date: 2022-10
Authors: Mauricio Gonzalez-Garcia; Emily Rincon-Alvarez; Maria Laura Alberti; Mauricio Duran; Fabian Caro; Maria Del Carmen Venero; Yuri Edison Liberato; Ivette Buendia-Roldan Journal: Front Med (Lausanne) Date: 2021-06-17